Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen, Novartis Are Investors In Atlas Venture’s Ninth Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.

Advertisement

Related Content

Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund
Series A Financing For Annovation Includes Potential Buyout By TMC
Merck Adds Flagship To Its Venture Fund Network
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Unnamed Lilly "Mirror Fund" Acquires First Two Compounds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel